LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$909.04 |
| 52 Week High | US$909.57 |
| 52 Week Low | US$434.34 |
| Beta | 0.36 |
| 11 Month Change | 12.52% |
| 3 Month Change | 16.85% |
| 1 Year Change | 95.71% |
| 33 Year Change | 293.30% |
| 5 Year Change | 694.48% |
| Change since IPO | 32,266.37% |
Recent News & Updates
Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)
Jun 24Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Jun 17Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Jun 11Recent updates
Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis)
Jun 24Eli Lilly And Alzheimer's Disease: The Paucity Of Progress
Jun 17Eli Lilly Continues To Climb As Alzheimer's Drug Gains FDA Approval
Jun 11These 4 Measures Indicate That Eli Lilly (NYSE:LLY) Is Using Debt Reasonably Well
Jun 10
Eli Lilly's Growth And Challenges: A Cautious Buy
Jun 01Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
May 26Eli Lilly: Bloated Stock
May 01What You Can Learn From Eli Lilly and Company's (NYSE:LLY) P/S
Apr 22Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | 1.0% | 0.3% |
| 1Y | 95.7% | 19.1% | 22.5% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 19.1% over the past year.
Return vs Market: LLY exceeded the US Market which returned 22.5% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months.
Volatility Over Time: LLY's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$811.50b |
| Earnings (TTM) | US$6.14b |
| Revenue (TTM) | US$35.93b |
133.3x
P/E Ratio22.8x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$35.93b |
| Cost of Revenue | US$7.13b |
| Gross Profit | US$28.80b |
| Other Expenses | US$22.66b |
| Earnings | US$6.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | 6.82 |
| Gross Margin | 80.16% |
| Net Profit Margin | 17.08% |
| Debt/Equity Ratio | 204.3% |
How did LLY perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield69%
Payout RatioDoes LLY pay a reliable dividends?
See LLY dividend history and benchmarks| Eli Lilly dividend dates | |
|---|---|
| Ex Dividend Date | Aug 15 2024 |
| Dividend Pay Date | Sep 10 2024 |
| Days until Ex dividend | 47 days |
| Days until Dividend pay date | 73 days |
Does LLY pay a reliable dividends?
See LLY dividend history and benchmarks